Did You Know?

Editor’s Picks

Latest News

Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg...

New Study Shows Cortical Disarray Measurement (CDM®) Can Reflect Microscopic Patterns of Pathology in Frontotemporal Dementia

Research presented at ISFTD 2026 connects measurements from the living brain with disease patterns confirmed through postmortem analysis Mapping cortical...

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new...

Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences

VANCOUVER, British Columbia, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage...

Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial

Dutch Cardiovascular Investigator Network (WCN) Leads European Enrollment in Phase 3 Study Evaluating Etripamil Nasal Spray for AFib-RVRMONTREAL and CHARLOTTE, N.C., Oct....

error: Content is protected !!